A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Phase 1 Completed 71 enrolled Genentech, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This multicenter, open-label, dose-escalating study will assess the safety, tolerability, and pharmacokinetics of DMOT4039A in participants with unresectable pancreatic or platinum-resistant ovarian cancer. Cohorts of participants will receive multiple ascending intravenous doses of DMOT4039A.

Timeline

Start: 2011-11
Primary completion: 2015-12
Completion: 2015-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RG-7600	Unknown	0.2 mg/kg	Intravenous

A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Summary

Timeline

Drugs

Indications